Head and Neck Cancer Research
HPV Vaccine May Provide Men with “Herd Immunity” against Oral HPV InfectionsPosted:
Oral HPV infections cause over 70% of all oropharyngeal cancers in the United States. In a new study of adults aged 18‒59, the rate of HPV vaccination rose from 0% to 6% for men, while oral HPV infections fell by 37% among unvaccinated men.
Cetuximab with radiation found to be inferior to standard treatment in HPV-positive oropharyngeal cancerPosted:
Results from a randomized clinical trial show patients with HPV-positive oropharyngeal cancer treated with radiation and cetuximab had inferior survival compared to the current standard treatment with radiation and cisplatin. The trial’s goal was to find a less toxic treatment approach without compromising survival.
HPV Vaccination Linked to Decreased Oral HPV InfectionsPosted:
A study of more than 2,600 young adults found that the prevalence of oral infection with four HPV types, including two cancer-causing types, was 88% lower in those who reported receiving at least one dose of an HPV vaccine than in those not vaccinated.
Nivolumab Improves Survival for Patients with Recurrent Head and Neck CancerPosted:
Results from a phase III trial showed that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma.
FDA Approves Nivolumab for Head and Neck CancerPosted:
The FDA has approved nivolumab for squamous cell carcinoma of the head and neck that has progressed during chemotherapy with a platinum-based drug or that has recurred or metastasized after platinum-based chemotherapy.
FDA Approves Pembrolizumab for Head and Neck CancerPosted:
FDA granted pembrolizumab an accelerated approval for patients with recurrent or metastatic head and neck cancer that has continued to progress despite standard treatment with chemotherapy.
PET-CT–Guided Surveillance May Reduce Need for Surgery in Some Patients with Advanced Head and Neck CancerPosted:
Patients with advanced squamous cell carcinoma of the head and neck who underwent PET-CT–guided surveillance after chemoradiation had overall survival rates similar to those of patients who underwent planned neck dissection and chemoradiation. But PET-CT imaging resulted in fewer operations and was more cost-effective than neck dissection.
Prospective Study Links HPV Detection in the Mouth to Head and Neck CancerPosted:
A new study confirms that infection with HPV 16 precedes the development of head and neck cancer.
Genome Study Yields Clues to Head and Neck CancersPosted:
Researchers have surveyed the genetic changes in nearly 300 head and neck cancers, revealing some previously unknown alterations that may play a role in the disease, including in patients whose cancer is associated with the human papillomavirus (HPV).
NIH-funded study uncovers range of molecular alterations in head and neck cancers, new potential drug targets; TCGA tumor genome sequencing analyses offer new insights into the effects of HPV and smokingPosted:
Investigators with The Cancer Genome Atlas (TCGA) Research Network have discovered genomic differences – with potentially important clinical implications – in head and neck cancers caused by infection with the human papillomavirus (HPV).